assessment of abdominal symptoms and intestinal inflammation in children and adolescents with cystic fibrosis without highly effective modulator therapy

Original title: “Assessment of abdominal symptoms and intestinal inflammation in children and adolescents with cystic fibrosis without highly effective modulator therapy.”

homozygous 896delt c 764del in somali american siblings with cystic fibrosis

Original title: “Homozygous 896delT (c.764del) in Somali-American Siblings With Cystic Fibrosis.”

determinants of health related quality of life in adults with cystic fibrosis the role of selected sociodemographic and treatment related factors

Original title: “Determinants of health-related quality of life in adults with cystic fibrosis: the role of selected sociodemographic and treatment-related factors.”

elexacaftor tezacaftor ivacaftor is safe and effectively reduces sino nasal symptoms in people with cystic fibrosis post lung transplantation

Original title: “Elexacaftor/tezacaftor/ivacaftor is safe and effectively reduces sino-nasal symptoms in people with cystic fibrosis post lung transplantation.”

pkc activators improve the function of biogenesis deficient cftr channels

Original title: “PKC activators improve the function of biogenesis-deficient CFTR channels.”

patient derived intestinal organoids in the global cystic fibrosis landscape

Original title: “Patient-Derived Intestinal Organoids in the Global Cystic Fibrosis Landscape.”

tracking early cystic fibrosis in the new era

Original title: “Tracking early cystic fibrosis in the new era.”

safety of inhaled levofloxacin in people with cystic fibrosis data from uk and german registries

Original title: “Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries.”

outcomes of sars cov 2 infection post solid organ transplantation in the cystic fibrosis population

Original title: “Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population.”

therapeutic approaches for nonsense mutations in cftr

Original title: “Therapeutic approaches for nonsense mutations in CFTR.”

Columnist Lara Govendo shares her thoughts about Rare Disease Day, and how living with cystic fibrosis shapes her advocacy. Despite days being set aside to observe them, a lack of awareness about rare diseases remains. There is less research, funding, and advocacy. Still, I’m so rare that my own gene mutations are among the 10% of the CF population for which modulators do not help. I won’t go into how disheartening it is to see others living relatively normal lives while a small group of us watch on the sidelines. Just know that we’re still out here, waiting on our miracle drug. ... Some diseases remain at the forefront of our minds because they affect many people. Through ad campaigns, celebrity endorsements, and corporate support, these diseases take center stage and receive more funding for research, clinical trials, and support groups. I don’t mean to suggest that getting more attention diminishes their seriousness. It’s not a competition. No disease should be celebrated. But Rare Disease Day asks us to focus on disease communities that don’t often get much attention. I didn’t know much about other rare disease communities until I connected with them. It’s impossible to have the bandwidth to know about everything. That’s totally valid, and I feel that on a soul level. For that reason, I’m grateful, ultimately, that days like Rare Disease Day exist.

Original title: “While living with cystic fibrosis, every day is Rare Disease Day for me”

adult ileocolic intussusception in a patient with cystic fibrosis diagnostic role of point of care ultrasound case report

Original title: “Adult Ileocolic Intussusception in a Patient With Cystic Fibrosis: Diagnostic Role of Point-of-Care Ultrasound 'Case Report'.”

Washington, DC, Feb. 03, 2026 (GLOBE NEWSWIRE) -- National Association of Specialty Pharmacy (NASP) President and CEO Sheila Arquette, R.Ph. and Chairman... Specialty pharmacies serve communities of patients who have complex health conditions like cancer, rheumatoid arthritis, multiple sclerosis, cystic fibrosis, hemophilia, organ transplantation and rare diseases. Specialty pharmacies are accredited by an independent, third party nationally recognized accreditation organization ensuring consistent quality of extensive drug management and clinical patient care services. NASP has long advocated for this law, which we believe will stabilize and strengthen the specialty pharmacy infrastructure that complex therapies depend on—supporting innovation, adherence, and improved long-term outcomes for patients with cancer, autoimmune diseases, rare disorders, and other serious conditions,” said Scott Guisinger. For too long, specialty pharmacies have faced underwater reimbursement, opaque practices, and restrictive networks that have forced many qualified providers out of network and disrupted continuity of care for some of the sickest patients in America. This landmark federal action represents the most significant step yet toward ending those practices,” said Sheila Arquette. 22, 2026 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) applauds the House for taking decided action today to enact reforms to support Medicare... Read More · January 21, 2026 15:31 ET | Source: National Association of Specialty Pharmacy (NASP) Pharmacist and Pharmacy Organizations Including NASP Commend 2026 Spending Bill with Important PBM Provisions, Urge Passage · Washington, DC, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The National Community Pharmacists Association, the National Association of Chain Drug Stores, FMI – The Food Industry Association, the National...

Original title: “NASP Applauds Congressional Passage of Landmark Bill to Protect Patient Access to Specialty Pharmacies and Support Specialty Pharmacy Businesses”